Suchitra Sundaram, MD, shares key insights in chronic lymphocytic leukemia (CLL) from ASH 2024. Fixed-duration combinations, such as acalabrutinib and venetoclax, showed improved progression-free survival and potential for treatment de-escalation based on minimal residual disease (MRD) testing.
Promising results were also presented for epcoritamab, a CD20 bispecific antibody with a 61% overall response rate in refractory CLL; and emerging BTK degraders, which demonstrated efficacy in heavily pretreated patients. These advances underscore a shift toward more precise and effective CLL therapies, addressing unmet needs in resistant patient populations.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASH 2024: Transformative Advances in CLL Treatment - Medscape - Dec 13, 2024.
Comments